IRCT20161010030246N6Not yet recruitingPhase 3
Evaluating the effectiveness of silymarin in preventing vancomycin-induced nephrotoxicity in hospitalized patients
Conditions
Trial Snapshot
- Phase
- Phase 3
- Status
- Not yet recruiting
- Enrollment
- 80
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 18 years to no limit (—)
- Sex
- All
Inclusion Criteria
- •Hemodynamic stability (mean arterial blood pressure above 70 mmHg and/or systolic blood pressure above 90 mmHg.
- •Willingness to participate in the study
- •Receiving vancomycin intravenously for at least 1 week with the maintenance dosage regimen of 30-45 mg/kg/day or 1-2 g twice a day. Notably, the vancomycin regimen is the same in both hospitals.
Exclusion Criteria
- •Confirmed history of acute kidney injury
- •Confirmed history of chronic kidney disease
- •Taking vancomycin within the last 14 days
- •Taking silymarin orally at least during the past day
- •Confirmed history of hypersensitivity reactions following oral consumption of silymarin
- •Simultaneous use of agents with antioxidant activity such as vitamin C, vitamin E, vitamin A, melatonin
- •Receiving drugs with high nephrotoxicity potential such as aminoglycosides, amphotericin b, colistin
- •Oral intolerance to drugs
Investigators
Similar Trials
Recruiting
Phase 3
Evaluating the effectiveness of Silymarin on the prevention of gentamicin nephrotoxicityGentamicin-induced renal toxicity in hospitalized patients.Other bacterial diseasesA30-A49IRCT20161010030246N3Shiraz University of Medical Sciences60
Not yet recruiting
Phase 2
Silymarin capsule in COVID-19COVID-19 disease.COVID-19U07.1IRCT20180103038199N10Mashhad University of Medical Sciences140
Completed
Phase 2
To evaluate the effectiveness of Silymarin (Livergol) on IL-6 levels and size of endometrioma lesionsIRCT20150905023897N5Vice chancellor for research Tarbiat Modares University60
Recruiting
Phase 3
effects of Silymarin in the Prevention of hyperbilirubinemiaeonatal jaundice, unspecified.Neonatal jaundice, unspecifiedP59.9IRCT20231120060123N1Mashhad University of Medical Sciences120
Completed
Phase 3
The effect of silymarin on methadone poisoningIRCT20210216050377N1Shahre-kord University of Medical Sciences64